Tricol Biomedical, INC.

Tricol Biomedical is a fully integrated medical device company specializing in hemostatic and wound-care management solutions. The company develops and markets the HemCon product line, built around its proprietary chitosan technology (Chito+), designed to enable rapid bleeding control across three primary market segments: Trauma Management, Procedural Care, and Consumer Self-Care. Founded with a legacy tied to battlefield medicine (original 2001 partnership with U.S. Army), Tricol's hemostatic dressings utilize a polycationic charge mechanism that promotes binding with negatively charged tissue biopolymers to facilitate rapid hemostasis and enable the body's natural coagulation pathway. The product portfolio includes HemCon PRO dressings (trauma and procedural settings), OneStop Bandage (rapid bleeding control including patients on anticoagulants), ChitoGauze (minor wound bleeding control), and ChitoDot bandages (procedural puncture site management). Applications span pre-hospital and battlefield trauma, hospital procedural care (angiography, dialysis access, surgical hemostasis), dental surgery, and over-the-counter consumer first-aid use. The company serves military, emergency medicine, hospital procedural areas, dialysis centers, and direct consumers. Tricol maintains manufacturing and headquarters operations in Portland, Oregon, with a European subsidiary (HemCon Medical Technologies CZ) in the Czech Republic. The company emphasizes quality, innovation in bleeding control technology, and maintains sample evaluation programs for facility and medical professional assessment.